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Abstract
Background: International guidelines recommend ethical and scientific quality standards for managing and
reporting adverse events occurring during clinical trials to competent research ethics committees and regulatory
authorities. The purpose of this study was to determine whether clinical trial protocols in Cameroon are developed
in line with national requirements and international guidelines as far as detecting, reporting and investigating of
adverse events is concerned.
Methods: It was a documentary review of all approved clinical trial protocols that were submitted at the Cameroon
National Ethics Committee for evaluation from 1997 through 2012. Data were extracted using a preconceived and
validated grid. Protocol review process targeted the title, abstract, objectives, methodology, resources, and the
chapter on safety.
Results: In total, 106 (4.9 %) clinical trial protocols were identified from 2173 protocols seen in the archive and
104 (4.8 %) included for review. Seventy six (73.1 %) trials did not include the surveillance of adverse events as part
of their objective. A total of 91 (87.5 %) protocols did not budget for adverse event surveillance, 76 (73.1 %) did not
have a data safety management board (DSMB), 11(10.6 %) included insurance for participants, 47 (45.2 %) did not
include a case definition for serious adverse events, 33 (31.7 %) described procedures to detect adverse events,
33 (31.7 %) described procedure for reporting and 22 (21.2 %) described procedure for investigating adverse events.
Discussions: Most clinical trial protocols in Cameroon are developed to focus on benefits and pay little attention
to harms. The development of national guidelines can improve the surveillance of adverse events in clinical trial
research conducted in Cameroon. Adverse events surveillance tools and a budget are critical for an adequate
planning for adverse event surveillance when developing trial protocols.
Conclusion: Clinical trial protocols submitted in the Cameroon National Ethics Committee do not adequately plan
to assess adverse events in clinical trial protocols. In order to improve on the safety of participants and marketed
drug, there is a need to develop national guidelines for clinical trials by the government, and to improve evaluation
procedures and monitoring of ongoing trials by the ethics committee.
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Background
Unless information on harms is available, it is impossible
to make a balance between benefits and risk of an in-
vestigational product/intervention in a clinical/field trial
study. Scientific and ethical evidence have shown that
adverse events are not well accounted for during Clinical
trials [1, 2]. Clinical trials general aim to test the efficacy
and safety of the investigational products/intervention,
but many investigators/sponsors usually focus on the ef-
ficacy primarily because of fear that a proper assessment
of harms may cause more trouble and discredit, than the
fame and glory associated with successful reporting of
benefits [3]. This may affect the quality of the research
[4, 5], resulting to the production of drugs that are less
safe to populations that eventually need them.
International guidelines such as the International
Conference of Harmonization on Good Clinical Practice
(ICH-GCP), CONSORT extension for Harms(for report-
ing results of clinical trials), the WHO reporting guide-
lines and the WHO Strategy on Research for Health
recommend ethical and scientific quality standards for
designing, conducting, recording and reporting trials
that involve the participation of human participants.
Compliance with these standards provides public assur-
ance that the rights, safety and well-being of trial sub-
jects are protected in accordance with the Helsinki
Declaration, and that the clinical trial data are credible
[6–9]. They recommend researchers and sponsors to re-
port all adverse events resulting from clinical/field trials
to competent Research Ethics Committees and to Regu-
latory authorities. During the development of protocols
for such trials, these recommendations have to be taken
into consideration.
In Cameroon, the Pharmacovigilance unit is in charge
of drug safety surveillance while the National ethics
committee is involved in national regulatory authorities
of drugs and vaccines. There is political awareness of
pharmacovigilance and its role to ensure the safety of
pharmaceutical products [10] and on the organization
and functioning of the National ethics Committee for
the safety of research participants [11, 12]. But National
guidelines to regulate research involving human partici-
pants and clinical/field trials do not exist. Drugs are ad-
ministered in health facilities during clinical trials and in
some health programs, yet adverse event resulting from
these trials are usually not reported to these two bodies
as international guidelines recommend. This study was
therefore conducted on clinical trial protocols to assess
how much investigators and sponsors have planned to
assess adverse events during clinical trials. That is, how
much they have planned to collect data on adverse
events, investigate them and discuss objectively whether
or not the benefit outweighs the risk. This assessment
was done by determining the proportion of clinical trials
that included adverse events as part of the research ob-
jectives, outcomes and follow up variables. It also
assessed the resources, methods and procedures that
were used in the surveillance of adverse events. Findings
of this study will help to identify intervention needs to
ameliorate on the safety of research participants during
clinical trials conducted in Cameroon. It will also pro-
vide evidence to decision making that will help to im-
prove the respect of ethical and scientific standards of
conducting clinical research and the practice of pharma-
covigilance in Cameroon and other resource limited
countries.
Methods
This study was issued ethical clearance by the Cameroon
National Ethics Review Committee (CNERSH) with
reference number 2013/11/385/L/CNERSH/SP. A confiden-
tiality agreement was signed before access to the protocols
was granted. Personal information about the investigators or
sponsors was not collected. Data collection was anonymous.
It was a documentary review (cross-sectional study) of
approved clinical trial protocols that had been submitted
to the Cameroon National Ethics Committee for evalu-
ation from 1997 through 2012 inclusive. All hard copies of
eligible clinical trial protocols were reviewed line by line
and data was extracted on a grid.
The Cameroon National Ethics Review Committee is an in-
dependent body, from all political, institutional, professional
and economic influence. It is one of the major actors involved
in health research in Cameroon. Its main role is to safe-guard
the dignity, the rights, the security, the physical integrity and
the well-being of potential participants in research projects
conducted in Cameroon. It also ensures collaboration and
net-working with other ethics review boards at the national
and international levels. It is involved in the national regula-
tory authority of drugs and vaccines in Cameroon. It was cre-
ated in October 1997 by the ministerial order [11]. Since
then, it has been carrying out its activities. This study was
conducted in 2013, involving the review of clinical trial
protocols from 1997 through the year 2012 inclusive.
It was an exhaustive study. All clinical trial protocols
that were submitted for evaluation at the CNERSH since
its creation in 1997 were targeted. Approved protocols
that were being implemented or that were to be imple-
mented were eligible for review and were included in the
study while unapproved protocols and protocols that
were still under review were excluded (See Additional
file 1: Operatioanl Definitions used).
All protocols received by the CNERSH are eventually
archived both as hard and electronic copies. In the phys-
ical archive system of hard copies, clinical trial protocols
are not separated from other research protocols involv-
ing the participation of human subjects. It was therefore
necessary to first identify and separate all clinical trial
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protocols from the others. To do this, all archived proto-
cols from 1997 through 2012 were reviewed one after
the other chronologically according to the way they were
physically arranged in the archive system. The Title, ab-
stract and objective of each protocol was reviewed line
by line in order to identify protocols that were clinical
trials. Once a clinical trial protocol was identified, it was
attributed a code and kept aside for the next stage that
involved a detail review for data extraction. Four persons
were involved in this stage (two holders of a Master’s de-
gree in Epidemiology and two Medical doctors). The
CNERSH demands the submission of four hard copies
of research protocols for evaluation. Thus the four cop-
ies of a research protocol were reviewed by all four per-
sons of the team simultaneously. When there were
disagreements about the decision to include a protocol
as a clinical trial or not, reference was made to the
protocol and to standard definitions before decision tak-
ing. Once all clinical trial protocols were identified, they
were reviewed one after the other, in succession, and de-
pending on their identification codes, for data extraction.
Two persons who were holders of masters in Epidemi-
ology were involved at this stage. They simultaneously
reviewed each clinical trial protocol for data extraction.
When there was disagreement, reference was made to
the protocol and to international guidelines before deci-
sion taking.
In each clinical trial protocol, the following sections
were reviewed for data extraction; the cover page, ab-
stract, objectives, study design, methodology, implemen-
tation procedure, availability of insurance, budget, the
chapter on safety and the availability of a Data Safety
Management Board (DSMB). Each of the sections men-
tioned above were reviewed line by line to identify pa-
rameters of interest. Data collected from each protocol
was noted on a structured grid.
Regarding the availability of resources, protocols were
reviewed to see if there was a budget allocation for ad-
verse event surveillance, and if the budget incorporated
training on adverse event surveillance. The availability of
insurance welfare for research participants and the in-
clusion of a role to be played by the data management
safety board (DSMB) were also verified.
Regarding procedures or methods of adverse event
surveillance, parameters of interest included; the mode
of detection of adverse events, availability of persons
assigned to detect, and the existence of clear case defini-
tions of serious and minor adverse events. The proce-
dures or methods of adverse event reporting was
assessed with indicators that verified the availability of
persons to report, the reporting target for both expected
and unexpected adverse events, existence of a reporting
time frame, and reporting procedures. Assessment of
procedures or methods of adverse event investigation
were based on indicators that evaluated the procedures
of investigation, existence of stopping guidelines, exist-
ence of a plan to analyze data on adverse events and the
existence of plan to manage serious adverse events.
At the end of each working day, data collected by the
two data collectors were compared for differences. In case
there was a difference, reference was made to the original
protocol and to existing guidelines if need be and a reso-
lution was taken. Protocols that were in foreign language
(non-French or English) were reviewed with the help of
translators. Three translators were used; they were holders
of a master’s degree in the language involved. The lan-
guages were German, Spanish and Italian.
The data entry screen was created in Epi Info. There
was double data entry; that is the same data was entered
by two different persons, after which the databases were
compared for discrepancies and resolved using the utility
in Epi info labeled “Data compare”. All proportions were
calculated at 95 % confidence interval.
Results
A total of 2172 research protocols involving the partici-
pation of human subjects were seen in the archive.
Among these, 106 (4.9 %) were clinical trial protocols. In
total, 104 (4.8 %) were reviewed for data extraction. We
note that 31 (29.8 %) were locally sponsored trials while
71 (68.3 %) were internationally sponsored trials. The
Prisma flow diagram in Fig. 1 describes the procedure of
identification and selection of eligible clinical trial proto-
cols for review. We also note from Fig. 2 that the rate of
conducting clinical trials in Cameroon is on an increase.
The highest number of clinical trials conducted was be-
tween 2005 and 2011.
Adverse events as part of study objectives/outcome and
the availability of resources
We observe that 28 (26.9 %) protocols had at least one
objective that incorporated the assessment of adverse
events, 18 (17.3 %) had at least one adverse event as part
of the study outcome and 66 (63.5 %) included adverse
event among the variables to be followed-up.
In Fig. 3, we observe that the proportion of clinical
trial protocols that include the assessment of adverse
event as part of the study objectives shows an improve-
ment with time. Regarding the availability of resources,
13 (12.5 %) planned a budget for adverse event surveil-
lance. Among these, none had included budget for train-
ing on adverse event surveillance. Fourteen (13.5 %)
included adverse events in the sample size calculation,
11 (10.6 %) planned for a post-trial insurance welfare for
research participants, 28 (26.9 %) had a Data Safety
Management Board (DSMB) and 12 (11.5 %) had an in-
vestigator brochure.
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Procedures of adverse event detection
We observed that 31 (29.8 %) planned to use an ac-
tive surveillance technic to detect adverse events
while 10 (9.6 %) planned to use passive surveillance.
Also, 45 (43.3 %) did not specify the technique they
would use to detect adverse events while 15 (14.4 %)
planned to use a mixed (active and passive) technique
to detect adverse events. Table 1 shows some parame-
ters needed in the surveillance of adverse events and
that were assessed, stratified by sponsors. We observe
Fig. 1 Flow diagram to describe the procedures of identification and inclusion of clinical trial protocols for review
Fig. 2 Evolution in the number of clinical trials conducted in Cameroon
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that in general, internationally sponsored trials pro-
vide more parameters than locally sponsored trials.
Adverse events reporting procedures
In 36 (34.6 %) protocols, someone was assigned in charge
of reporting adverse events. Twenty eight (26.9 %) in-
dicated the investigator as the one in charge of reporting,
66 (47.1 %) did not specify persons in charge for reporting
adverse events, 40 (38.5 %) specified the time limit during
which any detected serious adverse event must be re-
ported to the appropriate body, and 33 (31.7 %) had a
clearly described procedure to report serious adverse
events. Table 2 shows the distribution of the specified time
frame for reporting adverse events as identified in the
reviewed clinical trial protocols by sponsors. We observed
that internationally sponsored trials adhere to recommen-
dations better than locally sponsored trials.
Adverse events investigation procedure
Among the 104 reviewed protocols, 23 (22.1 %) planned
to manage serious adverse events, 6 (5.8 %) planned to
manage unexpected serious adverse events, and 22 (21.2 %)
described a procedure to investigate any adverse event
that will be detected in the course of the trial. Thirty five
(33.7 %) had a stopping guideline or conditions to stop
the trial for serious adverse events and 24 (23.1 %) de-
scribed a plan to analyze adverse event data.
Discussions
This study intended to determine how much researchers
have planned to assess adverse events in clinical trial stud-
ies conducted in Cameroon. This evaluation was done
through the review of approved clinical trial protocols at
the Cameroon National Ethics Committee. Protocols need
to be evaluated by research ethics committees (RECs) to
assess whether all scientific, ethical, and legal require-
ments for conducting research with human subjects are
met [13, 14]. The key findings of this study indicated that
26.9 % of clinical trials conducted in Cameroon included
the surveillance of adverse events as part of the objective.
Similarly, 17.3 % included adverse events as part of the
study outcome under investigation. Regarding adverse
event surveillance procedures, 31.7 % described a proced-
ure for detecting, 31.7 % for reporting and 21.2 % de-
scribed a procedure to investigate adverse events. It was
noted that 12.5 % of the protocols included a budget for
adverse event surveillance. Also, 13.5 % included adverse
events in the sample size calculation and 10.6 % planned
for participant’s insurance care. Few trials (28.9 %) indi-
cated a role to be played by the DSMB, 33.7 % had a stop-
ping guideline and 41.7 % had a case report form.
Over the past two decades, we observe a steady in-
crease in the number of clinical trials conducted in
Cameroon until 2012 where we see a sudden decrease.
A possible explanation to the sudden drop in 2012 may
Fig. 3 Evolution of the number of protocols that include the assessment of adverse events as part of the objectives of the trials
Table 1 Description of parameters regarding the detection of adverse events
National sponsors International sponsors
Indicator Observation Yes (%) Yes (%) Total (%)
Persons assigned to detect adverse events 104 4 (3.8) 37 (35.6) 41 (39.4)
Defined a minor adverse event 104 4 (3.8) 53 (51.0) 57 (54.8)
Defined a serious adverse event 104 4 (3.8) 53 (51.0) 57 (54.8)
Indicated a time frame to detect adverse events 104 3 (2.9) 41 (39.4) 44 (42.3)
Described a Procedure for detecting adverse events 104 2 (1.9) 31 (29.8) 33 (31.7)
Case Report Form 96 4 (3.8) 35 (33.7) 39 (37.5)
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be due to the fact that the ministerial decision in April
2012, resulted to the restructured, organization and func-
tioning of the CNERSH [12]. After which its office that
was initially located in Bastos adjacent to Lycee le
Nkoleton since it was created was then transferred to the
Ministry of Public Health. We can also estimate from the
results of this study that clinical trials make up about 5 %
of all research conducted on human subjects in
Cameroon. We also noted that the number of clinical tri-
als conducted in Cameroon is significantly different from
that recorded in the WHO Clinical trial Registry. A study
published in 2011 through a simple search by location on
the clinical trial website https://clinicaltrials.gov/ revealed
24 Clinical trials in Cameroon. On the WHO Inter-
national clinical trial Registry Platform (ICTRP), the num-
bers were similar whereas in this study, by that same year
(2011), we identified 99 clinical trial protocols. This indi-
cates that many clinical trials that are conducted in
Cameroon are not registered in the clinical trial registry.
This study did not explore the reasons for the low regis-
tration rate of clinical trials being conducted in Cameroon
though we believe that it may be due to lack of awareness
or motivation.
The International Conference of Harmonization on
Good Clinical Practice (ICH-GCP),the WHO guidelines,
the WHO Strategy on Research for Health, and the
Consolidated Standard for Reporting Trials (CONSORT)
extension on Harms recommend ethical and scientific
standards for conducting, and reporting results of clinical
trials. Clinical trials need to be developed carefully to give
a fair and balance report between risks and benefits, wher-
ever the research is conducted [15–17]. Clinical trials have
a goal to assess the safety and efficacy of the product/
intervention under investigation [6]. In order to say that
the product is safe and effective for human use, a fair bal-
ance assessment of both the efficacy and safety must be
made and the benefits must outweigh the risk. It is there-
fore impossible to make this balance when data/informa-
tion on either of safety and efficacy is lacking. In this
study, we observed that most protocols did not include
the assessment of adverse events as part of the study ob-
jectives and outcomes. This is an indication that most of
the trials were focusing on the benefits, confirming the
findings of a study that showed that less attention is given
to assess harms than benefits during clinical trials [1, 2].
Though we did not explore factors that are contributing
to this, we think that the lack of budget, limitation in
knowledge of researchers in conducting research in ac-
cordance with the methods and procedures of good clin-
ical practice or the fear that a proper assessment of harms
may cause discredit of the research findings could be some
of the reasons. Similar studies have shown this [3].
Adverse events surveillance needs to be considered
when budgeting for clinical trials. The detection of ad-
verse events during clinical trials requires that the sam-
ple size be large enough to increase the statistical power
to detect adverse events. It is therefore vital to consider
adverse events when calculating the sample size so that
it will be large enough to be able to detect adverse
events. A large sample size will definitely require an in-
crease in budget as well. This study has indicated that
few clinical trials budgeted to survey adverse events.
That can be proven by the fact that only 14 (14.9 %) of
the trials included adverse events in the sample size cal-
culation. This is evidence that little attention is given to
assess the safety of the products under investigation.
In Cameroon, one of the key requirements for obtain-
ing administrative clearance for clinical trials involving
human subject participants is a signed insurance docu-
ment [10]. This document engages the investigators and
sponsors to manage all cases of adverse events, both
short term or long term that may occur during the trial.
This study has shown that globally, more than 90.4 % of
the trials did not plan any insurance for participants.
This implies that participants of such studies will be li-
able to both physical damage (such as pains, incapacities
and even deaths) and economic consequences (direct
and indirect cost of treatments and rehabilitation) all by
themselves in case they suffer from an adverse event.
Looking at this, pre and post the arête of 2009, only
2 % of the protocols planned insurance for participants
before 2009. This low proportion can be explained by
the fact that there was no decision regulate the conduct
Table 2 Description of reporting targets of suspected Adverse





When to report adverse events Frequency Frequency
Serious adverse events
No later than 1 hour 0 0
No later than 24 hours 0 31
No later than 7 days 1 2
No later than 15 days 0 1
Others 0 5
Did not specify 30 32
Total 31 71
Unexpected adverse events
No later than 1 hour 0 1
No later than 24 hours 0 12
No later than 7 days 1 1
No later than 15 days 0 3
Others 0 6
Did not specify 30 48
Total 31 71
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of clinical trials. However, after 2009, the situation that
was devastating (2 %) now improved to about 10.6 %. We
expected this proportion to be higher, this can be ex-
plained by the fact that many of the reviewed protocols
were field trials and other types of intervention trials stud-
ies that did not necessarily required the insurance of par-
ticipants. We can thus say that the adherence to national
requirements and to international guidelines concerning
the insurance of research participants during clinical trials
in Cameroon is improving though a lot still needs to be
done to become standard.
Adverse event surveillance during clinical trials involves
the detection, reporting to the appropriate body (Sponsor
or regulatory authorities) within acceptable time limits
depending on the seriousness of the event and the investi-
gation of adverse events to determine a causality relation-
ship with the substance being investigated. These
procedures have to be clearly described in clinical trial
protocols and respected whatever the type or phase of the
clinical trial concerned. This study found out that these
procedures are not well elaborated in clinical trial proto-
cols to be implemented in Cameroon. According to the
ICH GCP and WHO guidelines for good clinical practice,
these procedures should include specifications such as
who should detect, when to detect, how to detect, when
to report, where to report, how to report and how to in-
vestigate any detected adverse events during the trial. We
noted that most of the protocols did not specify those im-
portant elements. For example, 60.6 % did specify who de-
tects adverse events during the trial and 52.9 % specified
who should report adverse events. This confirms the find-
ings of a studies that have revealed that in most clinical
trials (especially large trials), adverse events is usually self-
reported and is not independently verified [18]. Other
studies have also shown that there is a relative poor agree-
ment between self-reports and the active detection of ad-
verse events [19]. In the same trend, most did not state
the time limits of reporting based on the seriousness of
the adverse events. For example, serious adverse events
ought to be reported immediately and not later than 24 h
to the sponsors and to ethics review committees. Investi-
gating adverse events is vital to establish a causality rela-
tionship between the investigational product and the
adverse event, yet most of the protocols said nothing
about this. All these is evidence that adverse events are
not well accounted for during clinical trials in Cameroon
just as in most other settings [17]. From Tables 1, 2 and 3,
we clearly observe that most of the trials that did not
sufficiently plan to survey adverse events were locally
sponsored trials. This is due to the fact that national
guidelines to regulate the conduct of clinical trials do
not exist. It may also be due to lack of knowledge or
awareness of most local investigators/sponsors of clin-
ical trials in Cameroon.
The DSMB is vital in clinical trial. It assesses at inter-
vals the progress of a trial, the safety data, and the crit-
ical efficacy endpoints. It recommends to the sponsor
whether to continue, modify, or stop the trial based on
their assessment of the data. They have a well described
operational procedure and a stopping guideline. This
study found out that most of the trials did not have a
DSMB and a stopping guideline. The stopping guideline
provides evidence to the decision to stop or continue
the trial depending on safety and efficacy results. This
confirms the findings of studies that revealed that the
number of clinical trials that have been stopped earlier
has increased significantly over the past 15 years and
that most of them failed to report at least one of several
key details about the decision to stop the trial [20, 21]. For
example, it was also shown that prematurely stopped Ran-
domized Controlled Trials(RCT) often fail to adequately
report relevant information about the decision to stop
early [22]. We also observed that many of the protocols
did not have a case report form. The Case Report Form
(CRF) is a useful tool for collecting information on ad-
verse events during clinical trials. This form has to include
in the submitted protocol file to be evaluated. The fact
that most of the trials did not include this form is an indi-
cation that they were not ready to assess adverse events.
Some limitations of this study includes the fact that
only protocols in the national ethics committee were
reviewed and there were certainly some protocols that
were not submitted for ethical approval. Secondly, data
collection depended on the capacity of the data collector











Ethics Board 1 4






Ethics Board 1 3
Others 1 10
Not specified 29 50
Total 31 71
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to read, understand and collect the right information, in-
dicating that there might have been few issues of data
quality. But this was minimized firstly by selecting per-
sons who have acceptable knowledge on the subject ie
holders of master’s degree in Epidemiology and Medical
doctors, furthermore, they were trained on data collec-
tion process. We did not visit sites where clinical trials
are being conducted to verify these findings. We there-
fore recommend a more in-depth study to assess on-
going studies to confirm these findings.
Conclusion
Clinical trials protocols submitted at the Cameroon
National Ethics Committee do not adequately plan to as-
sess adverse events in clinical trial protocols. Researchers
and sponsors of clinical trials in Cameroon do not adhere
to national requirements and international norms and
standards when developing clinical trial protocols. There-
fore, the procedures of detecting and managing adverse
events needs to be improved in clinical trial research pro-
tocols submitted to the National Ethics Committee. In
order to improve this, we recommend the following:
1. Development of national guidelines to regulate the
conduct of clinical trials;
2. Make amendments to the standard operating
procedures for evaluating clinical trial protocols to
include parameters for the surveillance of adverse
events;
3. The use of standardize definitions of adverse events
and serious adverse events by researchers and local
and international authorities;
4. Providing guidelines to actors involved (researchers,
sponsors etc.), training actors on how to use
guidelines through seminars and workshops,
5. Encourage actors involved to important resources
sites such as the EQUATOR Network guidelines,
6. Promote the adherence to norms and guidelines
through periodic monitoring of ongoing trials
7. Considering adverse events surveillance when
making a budget.
8. We also recommend that the national ethics
committee should reinforce the capacity of its
members in clinical trial and pharmacovigilance and
reject protocols that do not sufficiently respect the
rights, safety and dignity of research participants.
9. We equally encourage a strong collaboration
between the national pharmacovigilance center and
the national ethics committee since they are the two
structures involved in drug safety surveillance and
national regulatory authority of drugs and vaccines
in Cameroon respectively;
10.Encourage researchers/sponsors to register clinical
trial research protocols and that the National Ethics
Committees should collaborate with registration
centers to ensure that all approved protocols are
registered;
11.This study should be replicated in other countries;
12.A follow up study should be conducted in 5 years to
see its evolution.
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